Recent Development in Carbohydrate-based Cancer Vaccines

Overview

Journal Curr Opin Chem Biol

Publisher Elsevier

Specialty Biochemistry

Date 2009 Sep 22

PMID 19766052

Citations 63

Authors

Zhongwu Guo

Qianli Wang

Affiliations

Soon will be listed here.

Abstract

Tumor-associated carbohydrate antigens (TACAs) are important molecular markers on the cancer cell surface, useful for the development of therapeutic cancer vaccines or cancer immunotherapies. However, because of their poor immunogenicity and/or immunotolerance, most TACAs fail to induce T cell-mediated immunity that is critical for cancer therapy. This review summarizes the recent effort to overcome this problem via constructing TACA conjugates with improved immunogenicity, such as by covalently coupling TACAs to proper carrier molecules to form clustered or multi-epitopic conjugate vaccines, coupling TACAs to a T cell peptide epitope and/or an immunostimulant epitope to form fully synthetic multi-component glycoconjugate vaccines, and developing vaccines based on chemically modified TACAs, which is combined with metabolic engineering of cancer cells.

Citing Articles

Targeting Siglec-Sialylated MUC1 Immune Axis in Cancer.

Ayyalasomayajula R, Cudic M Cancers (Basel). 2024; 16(7).

PMID: 38611013 PMC: 11011055. DOI: 10.3390/cancers16071334.

Cancer cells and viruses share common glycoepitopes: exciting opportunities toward combined treatments.

Roy R Front Immunol. 2024; 15:1292588.

PMID: 38495885 PMC: 10940920. DOI: 10.3389/fimmu.2024.1292588.

A Shiga Toxin B-Subunit-Based Lectibody Boosts T Cell Cytotoxicity towards Gb3-Positive Cancer Cells.

Tomisch J, Busse V, Rosato F, Makshakova O, Salavei P, Kittel A Cells. 2023; 12(14).

PMID: 37508560 PMC: 10378424. DOI: 10.3390/cells12141896.

Isolipoic acid-linked gold nanoparticles bearing the thomsen friedenreich tumor-associated carbohydrate antigen: Stability and studies.

Mondal U, Barchi Jr J Front Chem. 2022; 10:1002146.

PMID: 36300019 PMC: 9588967. DOI: 10.3389/fchem.2022.1002146.

Rhamnose-Containing Compounds: Biosynthesis and Applications.

Li S, Chen F, Li Y, Wang L, Li H, Gu G Molecules. 2022; 27(16).

PMID: 36014553 PMC: 9415975. DOI: 10.3390/molecules27165315.

References

Pan Y, Chefalo P, Nagy N, Harding C, Guo Z . Synthesis and immunological properties of N-modified GM3 antigens as therapeutic cancer vaccines. J Med Chem. 2005; 48(3):875-83. PMC: 3180873. DOI: 10.1021/jm0494422. View

Takano R, Muchmore E, Dennis J . Sialylation and malignant potential in tumour cell glycosylation mutants. Glycobiology. 1994; 4(5):665-74. DOI: 10.1093/glycob/4.5.665. View

Zinkernagel R . Localization dose and time of antigens determine immune reactivity. Semin Immunol. 2000; 12(3):163-71; discussion 257-344. DOI: 10.1006/smim.2000.0253. View

Slovin S, Ragupathi G, Musselli C, Fernandez C, Diani M, Verbel D . Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer. Cancer Immunol Immunother. 2005; 54(7):694-702. PMC: 11034220. DOI: 10.1007/s00262-004-0598-5. View

Slovin S, Keding S, Ragupathi G . Carbohydrate vaccines as immunotherapy for cancer. Immunol Cell Biol. 2005; 83(4):418-28. DOI: 10.1111/j.1440-1711.2005.01350.x. View

Keding S, Danishefsky S . Prospects for total synthesis: a vision for a totally synthetic vaccine targeting epithelial tumors. Proc Natl Acad Sci U S A. 2004; 101(33):11937-42. PMC: 514412. DOI: 10.1073/pnas.0401894101. View

Renaudet O, BenMohamed L, Dasgupta G, Bettahi I, Dumy P . Towards a self-adjuvanting multivalent B and T cell epitope containing synthetic glycolipopeptide cancer vaccine. ChemMedChem. 2008; 3(5):737-41. DOI: 10.1002/cmdc.200700315. View

Bertozzi C, Kiessling L . Chemical glycobiology. Science. 2001; 291(5512):2357-64. DOI: 10.1126/science.1059820. View

Zhu J, Wan Q, Ragupathi G, George C, Livingston P, Danishefsky S . Biologics through chemistry: total synthesis of a proposed dual-acting vaccine targeting ovarian cancer by orchestration of oligosaccharide and polypeptide domains. J Am Chem Soc. 2009; 131(11):4151-8. PMC: 2679991. DOI: 10.1021/ja810147j. View

10.

Grigalevicius S, Chierici S, Renaudet O, Lo-Man R, Deriaud E, Leclerc C . Chemoselective assembly and immunological evaluation of multiepitopic glycoconjugates bearing clustered Tn antigen as synthetic anticancer vaccines. Bioconjug Chem. 2005; 16(5):1149-59. DOI: 10.1021/bc050010v. View

11.

Cipolla L, Peri F, Airoldi C . Glycoconjugates in cancer therapy. Anticancer Agents Med Chem. 2008; 8(1):92-121. DOI: 10.2174/187152008783330815. View

12.

Ragupathi G, Cappello S, Yi S, Canter D, Spassova M, Bornmann W . Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines. Vaccine. 2002; 20(7-8):1030-8. DOI: 10.1016/s0264-410x(01)00451-0. View

13.

Zou W, Borrelli S, Gilbert M, Liu T, Pon R, Jennings H . Bioengineering of surface GD3 ganglioside for immunotargeting human melanoma cells. J Biol Chem. 2004; 279(24):25390-9. DOI: 10.1074/jbc.M402787200. View

14.

Ragupathi G, Livingston P, Hood C, Gathuru J, Krown S, Chapman P . Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clin Cancer Res. 2003; 9(14):5214-20. View

15.

Kudryashov V, Glunz P, Williams L, Hintermann S, Danishefsky S, LLOYD K . Toward optimized carbohydrate-based anticancer vaccines: epitope clustering, carrier structure, and adjuvant all influence antibody responses to Lewis(y) conjugates in mice. Proc Natl Acad Sci U S A. 2001; 98(6):3264-9. PMC: 30642. DOI: 10.1073/pnas.051623598. View

16.

Ochsenbein A, Klenerman P, Karrer U, Ludewig B, Pericin M, Hengartner H . Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci U S A. 1999; 96(5):2233-8. PMC: 26766. DOI: 10.1073/pnas.96.5.2233. View

17.

Carlstedt I, Davies J . Glycoconjugates facing the outside world. Biochem Soc Trans. 1997; 25(1):214-9. DOI: 10.1042/bst0250214. View

18.

Ragupathi G, Koide F, Sathyan N, Kagan E, Spassova M, Bornmann W . A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers. Cancer Immunol Immunother. 2003; 52(10):608-16. PMC: 11041859. DOI: 10.1007/s00262-003-0399-2. View

19.

Freire T, Bay S, Vichier-Guerre S, Lo-Man R, Leclerc C . Carbohydrate antigens: synthesis aspects and immunological applications in cancer. Mini Rev Med Chem. 2006; 6(12):1357-73. DOI: 10.2174/138955706778992996. View

20.

Wu J, Guo Z . Improving the antigenicity of sTn antigen by modification of its sialic acid residue for development of glycoconjugate cancer vaccines. Bioconjug Chem. 2006; 17(6):1537-44. PMC: 2532825. DOI: 10.1021/bc060103s. View